Azithromycin 1.5% Ophthalmic SolutionIn Purulent Bacterial or Trachomatous Conjunctivitis

被引：0
|
作者：
Karly P. Garnock-Jones
机构：
[1] Adis,
来源：
Drugs | 2012年 / 72卷
关键词：
Azithromycin; Tobramycin; Conjunctivitis; Ophthalmic Solution; Clinical Cure Rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The second-generation macrolide azithromycin is available as a 1.5% ophthalmic solution for use in the treatment of bacterial or trachomatous conjunctivitis. This article reviews the pharmacological properties of azithromycin 1.5% ophthalmic solution and its clinical efficacy and tolerability in patients with purulent bacterial conjunctivitis or trachomatous conjunctivitis caused by Chlamydia trachomatis.
引用
收藏
页码：361 / 373
页数：12
相关论文
共 50 条
  • [41] Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis
    McDonald, Marguerite B.
    Protzko, Eugene E.
    Brunner, Lynne S.
    Morris, Timothy W.
    Haas, Wolfgang
    Paterno, Michael R.
    Comstock, Timothy L.
    Usner, Date W.
    OPHTHALMOLOGY, 2009, 116 (09) : 1615 - 1623
  • [42] Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis
    Macejko, Thomas T.
    Bergmann, Mark T.
    Williams, Jon I.
    Gow, James A.
    Gomes, Paul J.
    McNamara, Timothy R.
    Abelson, Mark B.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 150 (01) : 122 - 127
  • [43] Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis
    Torkildsen, G. L.
    Gomes, P. J.
    Williams, J. I.
    Gow, J. A.
    McNamara, T. R.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S57 - S57
  • [44] The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment
    Dorfman, Mark S.
    Wagner, Rudolph S.
    Jamison, Tiffany
    Bell, Belinda
    Stroman, David W.
    ADVANCES IN THERAPY, 2008, 25 (03) : 208 - 217
  • [45] The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment
    Mark S. Dorfman
    Rudolph S. Wagner
    Tiffany Jamison
    Belinda Bell
    David W. Stroman
    Advances in Therapy, 2008, 25 : 208 - 217
  • [46] IQUIX (levofloxacin ophthalmic solution) 1.5% for the treatment of bacterial corneal ulcers
    不详
    CORNEA, 2007, : 1 - 7
  • [47] Safety of ophthalmic Moxifloxacin in the treatment of newborns, infants and toddlers, children, and adolescents with bacterial conjunctivitis
    Silver, LH
    Burkey, R
    Montgomery, D
    Gower, L
    Dickerson, J
    Crenshaw, K
    Potts, S
    Gross, R
    Schlech, B
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U231 - U231
  • [48] In Vitro Susceptibility to Different Topical Ophthalmic Antibiotics of Bacterial Isolates from Patients with Conjunctivitis
    Giardini, Franco
    Grandi, Giuseppe
    De Sanctis, Ugo
    Eandi, Chiara
    Machetta, Federica
    Pollino, Cristina
    Grignolo, Federico Maria
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2011, 19 (06) : 419 - 421
  • [49] A PLACEBO CONTROLLED TRIAL OF NORFLOXACIN OPHTHALMIC SOLUTION (NFX) IN ACUTE BACTERIAL CONJUNCTIVITIS (ABC)
    VOGEL, R
    LAIBOVITZ, R
    CASTAN, R
    MILLER, I
    WITTREICH, J
    COOK, TJ
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1992, 33 (04) : 937 - 937
  • [50] Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients
    Lichtenstein, SJ
    Rinehart, M
    JOURNAL OF AAPOS, 2003, 7 (05): : 317 - 324
12345